IGCPHARMA

NYSE AMERICAN: **IGC**

2025



Safe Harbor

The matters discussed in this presentation include forward-looking statements about the business prospects of IGC Pharma, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes, or similar expressions. Forward-looking statements reflect management's current expectations as of the date of this conference call and involve certain risks and uncertainties. The forward-looking statements are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments, and other factors that we believe are appropriate under these circumstances.

As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances. IGC Pharma, Inc.'s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors and the forward-looking statements are not guarantees of performance. Some of the factors that could cause future results to materially differ from recent results or those projected in forward-looking statements are included in our filings with the Securities and Exchange Commission (the "SEC"), such as our Annual Report on form 10-K filed with the SEC and subsequent filings on Form 10Q. We are under no obligation and expressly disclaim any obligation to update or alter the forward-looking statements, whether as a result of such changes, new information, subsequent events, or otherwise.

Highlights

- Diversified pipeline containing **multiple patent protected Alzheimer's Disease (AD) candidates** and **new GLP-1 candidates**
- **IGC-AD1 near-term opportunity** with Phase 2 CALMA trial in agitation – the **only** natural **THC-based** investigational **drug candidate** currently undergoing **FDA trials**
- **Long-term opportunity** with **new IGC-AD1 trial** in 2025 investigating potential to halt and modify Alzheimer's

Highlights

- Leading **artificial intelligence partnerships**
- **Poised for growth** with industry headwinds from Complementary & Alternative Medicine (CAM) Market
- **Vertically Integrated** manufacturing and production facilities
- **Clean capital structure**

IGC is Well Positioned in Two Large Addressable Markets

Alzheimer's Therapeutics Market[1]

$15.2B[1]

Market Size in 2030

19.99%

CAGR 2023- 2030

$4.2B

Market Size in 2022

[1] Grandview Research

Complementary and Alternative Medicine Market[1]

$1.2T[2]

Market Size in 2033

25%

CAGR 2024- 2033

$123.8B

Market Size in 2023

[2] Precedence Research

Our Pipeline

Asset	Preclinical	Phase I	Phase II	Phase III	Milestones
IGC-AD1	Targets NPS and AD pathology				Interim Phase 2 data available
LMP-platform	Targets NPS and AD pathology				Bio Equivalence to IGC-AD1 2025
TGR-platform	Targets Aβ plaques (Early- Moderate AD)				Tox study 2025
IGCM-platform	Targets Plaques and GLP-1				Tox study 2025
IGCC-platform	Targets Tau, 1A, 1B and 1C target GLP-1 and GIP				Tox study 2025

Protected Intellectual Property

Target	Description	Patent Applications	US Patents Granted	Foreign Patents Granted
(IGC-AD1)	Composition & Method for treating CNS Disorders.	7	1	
(IGC-AD1)	Composition & Method for treating CNS Disorders.	8	1	1
(TGR-63)	Naphthalene Monoimide Derivatives with ability to impact Aß protein build-up.	6		
(IGC-1C)	Naphthalene Monoimide Derivatives with ability to impact Tau aggregation and neurofibrillary tangle formation	1		
(IGC-M3)	Naphthalene Monoimide Derivatives with ability to impact Aß plaque buildup and neurofibrillary tangle formation	4		
Cancer (Naphthalene Dimdes)	Naphthalene diimide Derivatives with ability to self-assemble molecular interactions for biological and nonbiological systems		1	1
(IGC-LMP)	Composition, Synthesis & Medical use of Hybrid Molecule	1		
Epilepsy	Composition & Method for treating Seizures in humans & Cats/Dogs.	2	2	
Eating Disorders	Natural formulation with Cyproheptadine for treating Cachexia & Eating Disorders.	1	1	
Stuttering & Tourette Syndrome	Formulation for Treating Stuttering & Symptoms of Tourette Syndrome.	1		
Pain	Formulation containing Cobalamin and method for pain management.	1	2	2
		32	8	4

- In-house patents and applications
- Patents and applications acquired through exclusive license agreements

We have filed 32 patent applications, which are distributed among the US, Canada, Europe, Colombia, India, Mexico, Brazil, and Hong Kong.

Primary Target: Therapeutic Treatment for Agitation in Alzheimer's

Agitation: excessive motor activity, verbal aggression, or physical aggression impairing personal relationships, social functioning, and/or daily activities

Agitation starts early in AD and increases in severity as the disease progresses

40-80% of Alzheimer's patients suffer from agitation

Agitation is associated with:

- Higher admission rate to assisted living facilities
- Higher use of medications
- Long-term hospitalization
- Higher mortality

The Only "Treatment" Option Today

REXULTI® (brexpiprazole)

- A repurposed, atypical antipsychotic with a **black box warning**
- Costing patients $17,000 per year with a 6-10 week onset of action

BREXPIPRAZOLE BLACK BOX WARNING:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Our Solution

IGC-AD1

- A natural patent-protected compound in **Phase 2B trials**
- The **FIRST** compound that relies on low doses of THC, a cannabinoid, and another compound as active pharmaceutical ingredients ("API")
- The **ONLY** natural THC-based investigational drug candidate currently undergoing FDA trials

IGC-AD1 Phase 2 CALMA Trial: Ongoing

The study targets completion by
146 participants

Currently enrolled or completed:
50 patients

Multicenter, Double Blind, Randomized, Placebo-Controlled Trial

Objectives:

- Evaluate the safety and efficacy of IGC-AD1 on agitation in AD at week 2 and week 6

Key Inclusion Criteria:

- Diagnosis of probable AD using the NIA-AA criteria
- Clinically significant agitation using a score ≥4 in NPI agitation domain

Phase 2 Interim Results Indicate Drug Could Outperform Current Approved Therapy



- Brexpiprazole has limited effect at week 2
- Brexpiprazole starts to show effect at week 6
- Brex Cohen's d = 0.4, (p=.001) at week 12

- **CMAI score:** Cohen-Mansfield Agitation Inventory, a clinical tool used to assess and quantify agitation levels
- In this study, patients who took IGC-AD1 showed a **statistically significant improvement vs placebo in agitation over 6 weeks**
- IGC-AD1 demonstrates a large effect size (Cohen's d = 0.79) and is **more strongly distinguished from placebo at week 6 compared to the current approved therapy during its trial**

CMAI Least Squared mean change from baseline at EOT comparing active and placebo groups A) IGC-AD1 1ml BID trial (NCT05543681) and Brexpiprazole trial 0.5 to 2 mg flexible doses trial (NCT01922258). * p<0.05, ** p<0.01, b p<0.001; Mixed Model of Repeated Measures. SE: Standard Error; CMAI: Cohen-Mansfield Agitation Inventory.

Adverse Events: IGC-AD1 vs. Brexpiprazole

Brexpiprazole Trial

- **~6%** participants had **SAEs**
- **5% participants had AEs** leading to discontinuation
- **7 deaths reported**, 6 in the active group and 1 in placebo

IGC-AD1 Trial to date

- **No SAEs** reported up to 6 weeks
- **No AEs** leading to discontinuation
- **No deaths**

1. Data obtained from: Otsuka Pharmaceutical Company. (2023, April). BREXPIPRAZOLE FOR THE TREATMENT OF AGITATION ASSOCIATED WITH ALZHEIMER'S DEMENTIA SPONSOR BRIEFING DOCUMENT. https://www.fda.gov/media/167068/download

Secondary Target:
IGC-AD1
as a Disease Modifying Treatment

~400 million	50 million	7 million
Asymptomatic with AD pathology in their brains[1]	Diagnosed with AD worldwide[2]	Americans currently living with AD[2]

[1]Baylor University, October 2024

[2]2024 Alzheimer's disease facts and figures. Alzheimer's Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. PMID: 38689398; PMCID: PMC11095490

Our Preclinical Data



- IGC-AD1 inhibits Aβ plaque production by ~40%
- Non-disruptive to Amyloid Precursor Protein (APP)
- Reduces pTau/Tau implicated in tangles
- Improves spatial memory in APP/PS1 mouse model by 50%

*Results from N2a/AbetaPPswe Alzheimer's cell lines

J. Pineal. Res. 2011, 51, 75-86; J. Alzheimer's disease 2014, 42, 973-984; Int. J. Mol. Sci. 2022, 23, 2757; Int. J. Mol. Sci. 2022, 23, 4253

Phase 2 Mini Mental State Exam (MMSE) Interim Results



- MMSE, 30-point test, assess global cognitive status.
- It is widely used to detect cognitive impairment
- No negative impact on cognitive performance compared to placebo
- P value may be influenced by the small sample size and the adjustments for baseline scores, site variations, and visits.

Mean change (CI 95%)	Active	Placebo	Difference	Adjusted mean difference (95% CI))	p value
Scores	0.6 (-0.50, 1.71)	-0.3 (-1.23, 0.64)	0.9 (-0.56, 2.36)	0.515 (-0.497, 1.526)	0.319

Revenue Projections for Agitation in Alzheimer's

Item	North America And Europe		
	Adoption	Adoption	Adoption
Individuals with AD	15 million	15 million	15 million
Agitation in AD (76%)	11 million	11 million	11 million
% adoption of IGC-AD1	3%	5%	10%
Monthly Price of drug	$700	$700	$700
Estimated Revenue	**$2.7B**	**$4.6B**	**$9.2B**

- Only 1 FDA approved drug for agitation in Alzheimer's
- Potential to be disease modifying
- Accessible at an affordable price

www.alzheimer-europe.org/ - https://www.alz.org/ https://www.hsph.harvard.edu/news/press-releases/alzheimers-international-survey/ https://www.alzint.org/about/dementia-facts-figures/dementia-statistics

Next 18 months for IGC-AD1

1. Data read out for completed Phase 2 trial as a treatment for Agitation in AD

2. Seek FDA approval with potential commercialization, through compassionate use

3. Complete partial toxicology studies for IGC-AD1 for chronic use

4. Establish IGC-AD1 as a disease-modifying treatment

Potential Valuation Milestones





TGR Platform

TGR-63 Ameliorates Aβ Plaque



- **IGC licensed TGR** from India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR)
- Preclinical data testing demonstrates TGR-63 **holds potential to ameliorate plaque**
- Behavioral tests with AD (APP/PS1) mice show that TGR-63 can:
  - **Rescue neuronal cells from amyloid toxicity**
  - **Minimize learning deficiency, memory impairment and cognitive decline**

The Promise of TGR-63: Reduction of Plaque in Mouse Model

TGR-63 effectively reduced the amyloid burden in the mice cortex and hippocampus



The brain tissue sections were immunostained with amyloid fibrils specific primary antibody (OC) and red fluorescent-labeled secondary antibody


AI-Powered
Pharmaceutical Innovation

AI Powered Model for Alzheimer's

- IGC is building a Foundation Model for Alzheimer's that can help predict early markers and disease progression using data from around the world

- The model will be deployed on the web for doctors to use as a tool to help diagnose early Alzheimer's



Strategic Expansion into Metabolic Disorders

Leveraging AI-driven insights, IGC Pharma is expanding its portfolio to include GLP-1 agonists

GLP1$_r$



CB1$_r$



GIP$_r$

- Expansion into GLP-1 therapies allows IGC to tap into the **multi-billion-dollar global market** for weight management and type-2 diabetes treatments, while maintaining a strong foothold in Alzheimer's care
- Research indicates potential **synergies between neuroprotection and metabolic regulation via GLP-1** mechanisms, providing a unique, dual-therapy approach with IGC's proprietary molecules
- Diversifying the pipeline with GLP-1 candidates complements ongoing AD trials, enabling IGC to capitalize on emerging markets and create **substantial long-term value for shareholders**

Scientific Advisors

Chemistry and Pharmaceutical Sciences

Prof. Joseph Fortunak,
PhD
Professor
Chemistry and Pharmaceutical Sciences

Prof. Chuanhai Cao,
PhD
Professor of Pharmaceutical Sciences

Prof. T. Govindaraju,
PhD, FRSC.
Professor - Bioorganic Chemistry

Psychiatry and AI

Prof. Elliot Hong,
MD
Professor
Psychiatrist

Prof. James Saunders,
PhD
Ret.
Professor, Molecular Biology

Prof. Jeffrey Cummings,
MD, ScD, Chair of the ACTC Neuropsychiatric Symptoms Committee

Prof. Pablo Arbelaez,
PhD
Professor
Biomedical Engineering

Science Team

- Internal CRO to conduct and manage clinical trials
- Building a synthesis lab
- Partnered with manufacturers and top universities for AI and animal studies

Dr. Juan Orjuela, MD
Neuropsychiatrist

Dr. Juanita Arbeláez, MD, MPH
Medical Director

Evelyn Gutiérrez, Eng. MPH
CRO Manager

Diego Rodriguez, Ph.D.
Senior Chemist

Paola Ruiz, MS
AI Manager

Margarita Venegas, MS
Clinical Psychologist

Maria Tangarife, MS
Neuroscientist

Andres Sanchez, Ph.D.
Corporate Affairs Manager

Executive Management & Board

Executive management

Ram Mukunda,
CEO, Director

Claudia Grimaldi
VP & Director

Board

Richard Prins
Chairman

Ex. Congressman James Moran
Director

Terry Lierman
Director

Board Advisors

Governor
Terry McAuliffe

Amb. (Rtd) Howard Gutman

Join Us in The Fight to Conquer Alzheimer's

IGCPHARMA

www.igcpharma.com

NYSE AMERICAN: **IGC**

Thank you

Ram Mukunda

- ram@igcpharma.com

Claudia Grimaldi

- cgrimaldi@igcpharma.com